A Study of Fruquintinib in Adults With Metastatic Colorectal Cancer in Poland

Official record

Identifier

NCT07623174

Recruiting locations

country

Poland

Interventions studied

No intervention

Lead sponsor

Takeda

Target enrolment

110 participants

Study type

OBSERVATIONAL

Phase

Not provided in the official record

Status

Recruiting

First posted

Jun 3, 2026

Last updated on the registry

Sep 22, 2026

Age

18 Years

Sex

ALL

Study contact

The official record lists a study contact. Contact details are published there and are intentionally not copied to this page.

Eligibility criteria

Reproduced verbatim from the official record. Eligibility is decided by the study team, never by this page.

Inclusion Criteria:

1. Adult participants (aged 18 years and older) with mCRC who are eligible for treatment with fruquintinib under the national drug program B.4 and will receive fruquintinib as third or subsequent line treatment after progression on or intolerance to trifluride/tipiracil.
2. Participants who signed informed consent to participate in the study at the time of enrollment and prior to the fruquintinib treatment initiation.
3. Participants for whom adequate medical records are available to support the data collection requirements.

Exclusion Criteria:

1\. Participant currently participates or plans to participate in an interventional clinical trial.

Indexed under

Colorectal Cancer